S&P Futures
6,009.00 +5.25 (+0.09%) Dow Futures
43,923.00 +13.00 (+0.03%) Nasdaq Futures
21,237.50 +12.75 (+0.06%) Russell 2000 Futures
2,399.20 +3.50 (+0.15%) Crude Oil
71.23 -1.13 (-1.56%) Gold
2,696.30 -9.50 (-0.35%)
Roivant Sciences Ltd. (87S.F)
| Previous Close | 10.31 |
| Open | 10.41 |
| Bid | 10.40 x N/A |
| Ask | 11.43 x N/A |
| Day's Range | 10.41 - 10.43 |
| 52 Week Range | 7.55 - 11.48 |
| Volume | |
| Avg. Volume | 13 |
| Market Cap | 8.025B |
| Beta (5Y Monthly) | 1.24 |
| PE Ratio (TTM) | 1.95 |
| EPS (TTM) | 5.34 |
| Earnings Date | Nov 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRoivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024
BASEL, Switzerland and LONDON and NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 12, 2024, to report its financial results for the second quarter ended September 30, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Events & Pr
- GlobeNewswire
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
The acquisition expands Organon’s dermatology capabilities with a nonbiologic, non-steroidal topical treatment in the U.S.BASEL, Switzerland and LONDON and NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ: ROIV). Dermavant is a company dedicated to developing and commercializi
